Gilead Sciences (GILD) Cash Flow Statement

Click line-items for a historical chart and %

Net income	10.39B
Depreciation expense	129M
Amortization expense	737M
Stock-based compensation expenses	278M
Excess tax benefits from stock-based compensation	-162M
Tax benefits from employee stock plans
Deferred income taxes
Other non-cash transactions	-15M
Accounts receivable, net	770M
Inventories	-274M
Prepaid expenses and other assets	-785M
Accounts payable	-115M
Income taxes payable	1.03B
Accrued liabilities	1.06B
Deferred revenues	-148M
Net cash provided by operating activities	13.18B
Purchases of marketable securities	-19.88B
Proceeds from sales of marketable securities	10.38B
Proceeds from maturities of marketable securities	1.13B
Acquisitions, net of cash acquired
Capital expenditures and other	-579M
Net cash used in investing activities	-9.31B
Proceeds from issuances of senior notes, net of issuance costs
Proceeds from issuances of common stock	180M
Proceeds from credit facility
Repurchases of common stock	-10B
Repayment of convertible senior notes
Repayments of other long-term obligations
Excess tax benefits from stock-based compensation	162M
Distributions (to) from noncontrolling interest	-83M
Net cash used in financing activities	-7.05B
Effect of exchange rate changes on cash	137M
Net change in cash and cash equivalents	-3.04B
Cash and cash equivalents at beginning of period	12.85B
Cash and cash equivalents at end of period	9.81B

Entities mentioned with gild

View All Entities